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There is a growing realization that the gut–brain axis
plays a key role in maintaining brain health and the
stress response. Recently, the gut microbiota has
emerged as a master regulator of this axis. Thus,
opportunities to exploit the microbiome to treat
stress-related psychiatric disorders are materializing.
Clinical validation of such strategies is now warranted.definition of what exactly constitutes a healthy optimal“All disease begins in the gut.”
Hippocrates
The only effective pharmacological therapies devel-
oped so far for the treatment of common psychiatric dis-
orders target the monoaminergic systems within the
brain. The paradigm giving rise to such therapies dates
back to the 1950s, and efforts by the pharmaceutical in-
dustry to develop therapies based on alternative para-
digms have proved relatively fruitless. Over the past
decade another paradigm has begun to emerge, whereby
there is a growing realization that the gut–brain axis, the
bidirectional communication between the digestive tract
and the brain, plays a key role in maintaining brain health
and the stress response. More recently, the gut microbiota
has emerged as a master regulator of this axis. Indeed,
preclinical studies have shown that the microbiome is key
to normal neurodevelopment and behavior [1, 2], raising
the potential of targeting this microbiota–gut–brain axis
in the development of novel psychotropics [3]. This ap-
proach offers a promising new avenue for treating psychi-
atric conditions such as major depression or anxiety
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It has been postulated that the brain–gut–microbiota
axis plays a fundamental role in stress-related mental ill-
nesses [2]. The total mass of bacteria within the intestine
is approximately the same as that of the human brain,
and these bacteria have a highly rich and complex
biochemistry, comprising many more cells than the total
number of human cells. It is estimated that this ecosystem
has in excess of 1000 species and 7000 strains, but a
microbiota is missing. At the genomic level, the global
human gene complement is outnumbered by a factor of at
least 100 when compared to the gut microbiome [3].
Increasing evidence indicates that the microbiota exerts a
profound influence on brain physiology and ultimately on
behavior, including response to stress. Further investigation
is needed to understand fully how gut microbes influence
the brain. Many mechanisms have been shown to be
involved in this bidirectional pathway, including the vagus
nerve, immune activation, and production of microbial
metabolites and neurometabolites such as short chain fatty
acids, vitamins and neurotransmitters. Most of the com-
mon neurotransmitters in the human brain such as GABA,
5-HT and other monoamines can be produced by bacteria,
the implication of which is only slowly being unraveled.
How fundamental are gut microbes for brain function?
Studies from a number of research groups in Canada,
Sweden and Ireland have shown that, in germ-free
animals, the brain fails to develop normally in the absence
of the gut microbiome. Moreover, fundamental brain
processes such as myelination, adult neurogenesis and
microglia activation have also shown to be critically
dependent on microbiota composition. Bercik and col-
leagues [4] showed that it is possible to transfer behavioral
traits between mouse strains using fecal microbiota
transplantation: a transplant from an anxious mouse
produces an anxious phenotype while a transplant from a
non-anxious mouse produces a non-anxious phenotype.
They also found that transplantation alters brain chemis-
try in recipient ex-germ-free mice, suggesting that fecalrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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avenue for disorders such as depression or anxiety.
Depression and the microbiota
Major depression is a highly prevalent, debilitating
stress-related disorder and is recognized globally as one
of the significant causes of disability, with considerable
social consequences. The most consistently demonstrated
abnormality in depressed patients is hypothalamic–
pituitary–adrenal (HPA) axis dysregulation, manifested
as elevated cortisol and corticotropin releasing factor
(CRF). Furthermore, significant increases in the plasma
concentrations of pro-inflammatory cytokines are usually
observed.
Microbes exert a major influence on both the HPA
axis and on the immune system, compounding the link
between the microbiota and the stress response. Sudo
and colleagues [5] were the first to demonstrate that
germ-free mice who grew up in a sterile environment
have an exaggerated HPA axis response to an acute
stressor. It is noteworthy that this enhanced responsivity
of the HPA axis can be reversed by monoassociation
with a single bacterial strain, in this case Bifidobacterium
infantis. Published studies in rodents indicate that
treatment with this probiotic does impact on central
neurotransmitter functioning.
A number of years ago, together with Bienenstock and
colleagues at MacMaster University [6], we examined
the impact of a Lactobacillus rhamnosus strain (JB-1) on
anxiety- and antidepressant-related behavior, in addition
to neurochemical changes in mice. L. rhamnosus-treated
animals had lower levels of anxiety on a variety of
behavioral measures, which was concomitant with
alterations in the expression of both GABAA and
GABAB receptors across a variety of brain regions stud-
ied. Yet the question remained as to how a dietary intake
of a bacterial strain could alter brain and behavior. One
possible route of communication is via the vagus nerve.
To test this, animals underwent vagotomy or sham sur-
gery and were subsequently treated with L. rhamnosus or
an inactive control broth. Indeed, vagotomy prevented the
behavioral and neurochemical effects of the potential
probiotic strain, suggesting that L. rhamnosus could serve
as a potential antidepressant/anxiolytic via its (or one of
its metabolites) effects on the vagus nerve. Studies are
currently underway to examine the effect of this microbe
on stress responses in humans; preliminary results should
be available shortly.
In what is the largest study of the microbiome in
major depressive disorders to date, Jiang and colleagues
[7] analyzed fecal samples from 46 patients with major
depression and 30 healthy controls. The authors showed
that patients with depression could be stratified according
to their microbiome; acutely depressed patients hadhigher levels of Bacteroidetes, Proteobacteria and Actino-
bacteria, whereas levels of Firmicutes were significantly
reduced. A negative correlation was observed between
Faecalibacterium and the severity of depressive symptoms.
This study needs replication and further additional
questions need to be answered. Are there microbes
that confer a resilience against depression and are there
microbes that have a melancholic impact? Assuming
microbes influence mood, through which mechanisms do
they produce their effects?
Psychobiotics
Live bacteria that have a positive mental health
benefit have been defined as psychobiotics [1].
Several recent studies in healthy subjects suggest that
certain bacterial strains have psychobiotic activity
(see [8]). However, there is a need for much more
extensive placebo-controlled studies to be carried out
in both healthy volunteers and especially clinical
populations. Moreover, mechanistic studies focusing
on brain activity patterns are required. In this vein
we found that Bifidobacterium longum strain 1714
attenuated stress responses and enhanced cognition
in healthy subjects while altering electroencephalo-
graphic activity. Mayer’s group at the University of
California, Los Angeles (UCLA) found that a cocktail
of bacteria produced significant changes in central
physiology, as measured by altered activity in func-
tional magnetic resonance imaging (MRI) [9].
Until very recently, the literature on psychobiotics
was dominated by preclinical studies with little or no
effort at translation into humans. Fortunately, this
situation is now changing, with several human studies
being undertaken (see [8]). However, it may take a
cultural change for the food and probiotic industry to
carry out the level of investment required for such
clinical trials to prove efficacy. Moreover, preclinical
efforts focused at dissociating the mechanisms of
action of individual bacterial strains should also be
increased. Rational discovery of psychobiotics will
require the identification of potential therapeutic
targets, be it microbial metabolites or their effectors
at the receptor or cellular level of individual or a
consortium of strains.
Antimicrobials
Psychobiotics enable an increase in the level of “good”
bacteria within the intestine and offer a potentially safe
approach to treating stress-related conditions. Alterna-
tively, the elimination of certain microbes using selective
antimicrobial agents may have a positive mental health
benefit in some individuals. Preclinical studies and initial
patient-based studies indicate the potential of the
antibiotic minocycline as an antidepressant [10].
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negative bacteria, although it also exerts an influence
on immune mechanisms. It is tempting to speculate that
its action as an antibiotic produces an antidepressant
effect, at least in some patients.
Future
Only time will tell if the brain–gut–microbiota axis proves
a fruitful target for novel antidepressant development. It
seems likely that psychobiotics have a role to play in the
management of mild depression and anxiety states.
Although animal studies have been, and continue to be,
essential in deciphering the mechanisms underlying
potential psychobiotic effects, we now await future trans-
lation into human clinical investigations and the results of
large-scale placebo-controlled trials.
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